News of Note—Turnstone-La Jolla pact, Inovio-GeneOne and more


Here is some other vaccine news of note for the week:

> Under a new collaboration, Turnstone Biologics will use La Jolla Institute for Allergy and Immunology’s neoantigen identification methods to select personalized neoantigens for the development of cancer immunotherapies. Release

> Inovio and GeneOne Life Science have dosed the first patient in a phase 1 study of GLS-6150, a vaccine that aims to boost patients’ immunity against hepatitis C. Drug Development Technology article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> After posting positive topline results, Altimmune reported that its NasoVAX intranasal influenza vaccine candidate demonstrated a durable immune response for at least six months, while significant mucosal antibodies were also observed. Release

> A team at the University of California, San Diego, is developing an acne vaccine which has passed studies on animals and human acne samples. It’s seeking a company to collaborate on a clinical trial. U.S. News & World Report article

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.